Clinical trial
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Study timeline
Study start (actual)2022-03-12Date precision: day
Registry last updated2026-08-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
B-cell Acute Lymphoblastic Leukemiaunresolved
Obesityunresolved
Interventions
IDEAL2 InterventionBEHAVIORAL
Sponsors & collaborators
Etan Orgellead sponsor
Mapped research locations
HoustonTexas, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1AtlantaGeorgia, United States1San FranciscoCalifornia, United States1CincinnatiOhio, United States1PortlandOregon, United States1MinneapolisMinnesota, United States1DenverColorado, United States1Ann ArborMichigan, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05082519 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.